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pollution is responsible for 7 million deaths per annum, with 7%
of these attributable to pneumonia. Many of these fatalities have
been linked to exposure to high levels of airborne particulates,
such as diesel exhaust particles (DEPs).
Objectives: We sought to determine whether exposure to DEPs
could promote the progression of asymptomatic nasopharyngeal
carriage of Streptococcus pneumoniae to invasive pneumococcal
disease.
Methods: We used mouse models and in vitro assays to provide a
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1272and pneumococcal disease risk, and we confirmed our findings
by using induced sputum macrophages isolated from healthy
human volunteers.
Results: We demonstrate that inhaled exposure to DEPs
disrupts asymptomatic nasopharyngeal carriage of S
pneumoniae in mice, leading to dissemination to lungs and
blood. Pneumococci are transported from the nasopharynx to
the lungs following exposure to DEPs, leading to increased
proinflammatory cytokine production, reduced phagocytic
function of alveolar macrophages, and consequently, increased
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SHEARS ET AL 1273blood. These findings were confirmed by using DEP-exposed
induced sputum macrophages isolated from healthy volunteers,
demonstrating that impaired innate immune mechanisms
following DEP exposure are also at play in humans.
Conclusion: Lung inhaled DEPs increase susceptibility to
pneumococcal disease by leading to loss of immunological
control of pneumococcal colonisation, increased inflammation,
tissue damage, and systemic bacterial dissemination. (J Allergy
Clin Immunol 2020;145:1272-84.)
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Air pollution is a major environmental risk to health, with
outdoor air pollution estimated to cause 4.2 million premature
deaths worldwide in 2016 and household air pollution adding a
further 3.8 million deaths to the pollution-associated death toll.1
Of these deaths, 91% occurred in low- and middle-income coun-
tries, with respiratory (eg, asthma, chronic obstructive pulmonary
disease, lung cancer, and lower respiratory tract infections) and
cardiovascular diseases contributing to the largest disease
burden.2-19 Ambient air pollution can originate from natural sour-
ces, such as dust storms or forest fires; however, the vast majority
of air pollution is from anthropogenic sources such as heat and po-
wer generation, industrial activities, andmotor vehicles (both gas-
oline and diesel).20 Carbon monoxide, nitrogen dioxide, and
sulphur dioxide are responsible for many of the damaging effects
of air pollution; however, particulate matter (PM) is also associ-
ated with a wide range of health defects.21 PM is often divided
into 2 categories: PM10 (PM with an aerodynamic diameter be-
tween 2.5 and 10 mm) and fine PM (PM with an aerodynamic
diameter of <_2.5 mm).21 Both types of PM are associated with
increased hospital admissions for pneumonia in population
studies, particularly in industrialized countries.2-5
Streptococcus pneumoniae is the most common cause of
community-acquired pneumonia, with mortality rates of more
than 20% in patients with accompanying septicemia.22 The
pneumococcus is also the leading cause of infectious disease
deaths in children under the age of 5 years worldwide.22-24 S
pneumoniae is part of the normal flora of the human nasopharynx;
however, if the bacterium is able to gain access to normally sterile
sites such as the lungs, blood, and meninges, it has potential to
cause life-threatening disease such as pneumonia, septicemia,
and meningitis.22 Little is known about the conditions that allow
the bacterium to progress from a harmless commensal to a poten-
tially life-threatening pathogen; however, exposure to high levels
of pollution is a known risk factor for development of invasive
pneumococcal disease (IPD).2,3,25-28
We have previously identified a link between high levels of
airborne dust and epidemics of pneumococcal meningitis in the
Sahel region of Sub-Saharan Africa.29 In the developing world,
agricultural and household pollution are the major sources of
airborne PM; however, traffic and industrial pollution are increas-
ingly recognized as the biggest contributors to air pollution in
developed and industrialized countries.1,5,21,30,31 In particular,
there is a strong body of evidence to suggest that exposure to
diesel exhaust particles (DEPs), which are often used as a surro-
gate for traffic-related pollution, is linked to cardiovascular de-
fects in addition to respiratory disease.32-35 DEP inhalation has
been reported to increase lung inflammation and reduce lungfunction in rodent studies.36,37 DEP exposure has also been shown
to aggravate allergic airway inflammation and exacerbate asthma-
like inflammation.38-42 Additionally, DEP exposure has been
linked to impaired clearance of respiratory pathogens. Short-
term exposure to ambient concentrations of diesel engine emis-
sions impaired clearance of Pseudomonas aeruginosa and led
to increased lung inflammation and pathology in mousemodels,43
whereas intratracheal instillation of DEPs has been shown to
impair lung clearance of Listeria monocytogenes in rats.44 DEP
exposure has also been shown to enhance influenza infection of
respiratory epithelial cells in vitro, leading to increased oxidative
stress.45
Here, we provide mechanistic data to explain the association
between DEP inhalation and pneumococcal disease by using
murine models and in vitro assays. We show that upon inhalation
of DEPs, alveolar macrophages become congested with PM,
which significantly reduces their phagocytic ability, thereby im-
pairing bacterial clearance and increasing bacterial loads within
the lungs. DEP inhalation stimulates a proinflammatory environ-
ment, which is exacerbated by the high bacterial load. This highly
inflammatory environment caused by the combination of particu-
late and high bacterial load is likely to cause tissue damage, al-
lowing the bacterium access to the bloodstream. We also
provide data to suggest that DEPsmay provide metabolites to sus-
tain the survival of pneumococci within the lungs.METHODS
Bacteria and particulate
The mouse-virulent serotype 2 S pneumoniae strain D39 (NCTC 7466) was
cultured on blood agar base supplemented with 5% (vol/vol) defibrinated horse
blood or in brain heart infusion broth containing 20% (vol/vol) FBS. Bacteria
were identified as pneumococci by a-hemolysis on blood agar and by optochin
sensitivity. Bacterial suspensionswere standardized for inoculation and stored at
–808C.When required, suspensions were thawed at room temperature and bac-
teriawere harvested by centrifugation and suspended in PBS.DEPs (SRM2975)
were purchased from the National Institute of Standards and Technologies
(https://www-s.nist.gov/srmors/view_cert.cfm?srm52975).Mice
Female CD1, C57BL/6, or BALB/c mice (Charles River, Margate, United
Kingdom [UK]) were maintained in individually ventilated cages at
228C6 18C and 65% humidity with a 12-hour light-dark cycle. Mice were
acclimatized for 1 week before use and had free access to food and water. All
procedures were carried out on age-matched mice aged 6 to 8 weeks or older.
All experimental protocols were approved and performed in accordance with
the regulations of the Home Office Scientific Procedures Act (1986), Project
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Ethical Review Body.Mouse model of pneumococcal carriage
Mice were lightly anesthetized with a mixture of O2 and isoflurane and
exposed once daily to either 80 mg of DEPs dissolved in 40 mL of PBS or
PBS alone via the intranasal route for the duration of the experiment, unless
otherwise stated. After 3 exposures, mice were anesthetized before intranasal
infection with 13 105 colony-forming units (CFU) of D39 in 10 mL of PBS.
Controlmicewere treatedwith 10mL of PBS only.Micewere humanely killed
1, 4, 7, or 10 days postinfection. The nasopharynx and lungs were removed
from each mouse and blood was collected in heparin tubes. Bacterial viable
counts were determined as described previously.46 Lung cell suspensions
were stored at –808C following erythrocyte lysis and supernatants were also
stored at –808C until required. For histologic analysis, lungs of PBS- or
DEP-exposed mice were fixed overnight in neutral buffered formalin (10%
formalin) followed by 95% ethanol and processed using standard histologic
techniques. Six-micron frontal sections of the lungs were stained with hema-
toxylin and eosin and imaged using an Aperio CS2 Slide Scanner (Leica, Mil-
ton Keynes, UK). Apeiro Image Scope v12.3.2.8013 was used to analyze
images.Mouse model of pneumococcal pneumonia
Female BALB/c mice were exposed daily to 80 mg of DEPs in 40 mL of
PBS as described earlier in this article. After 3 intranasal exposures, micewere
intranasally infected with 1 3 106 CFU of D39 in 50 mL of PBS to induce
pneumococcal pneumonia. Mice were culled at either 24 or 72 hours postin-
fection and lung and blood viable counts were calculated as described earlier.Flow cytometry analysis
Single-cell suspensions from the lungs were stained as follows: panel 1,
CD45–fluorescein isothiocyanate (FITC) (30-F11, eBiosciences, Thermo
Scientific, Rugby, UK), CD4-APC-CY7 (RM4-5, BD Biosciences, Woking-
ham, UK), and FOXP3-Pacific blue (MF-14, Biolegend, London, UK); and
panel 2, CD45-FITC, GR1-PE-CY7 (RB6-8C5, BD Biosciences), CD11b-PE
(M1/70, Biolegend), and F4/80-Pacific blue (T45-2342, BD Biosciences).
Acquisition was carried out by using a FACSCanto flow cytometer (BD
Biosciences), and the analysis was performed using Flowjo X (Tree Star,
Ashland, Ore). Fluorescent minus 1 control for each of the included antibodies
were used to validate results.Cytokine analysis
Quantification of TNF-a, IFN-g, IL-1b, keratinocyte chemoattractant/human
growth-regulated oncogene (KC/GRO), macrophage inflammatory protein 2
(MIP-2), and IL-6 in lunghomogenateswasperformedbyusing aU-Plex cytokine
assay (Meso Scale Discovery, Rockville, Md) according to the manufacturer’s
instructions. Day 1 lung homogenates were diluted 2-fold, whereas day 4 and 7
lung homogenates were diluted 10-fold before the assay was run.Giemsa staining of murine alveolar macrophages
Mice were humanely killed at various time points and airway macrophages
were isolated by bronchoalveolar lavage (BAL) in 2 mL of PBS, as described
previously.47 The BAL fluid was fixed onto microscope slides by using a Cy-
tospin 4 (Thermo Scientific) at 1000 rpm. Slides were fixed with Kwik-Diff
Reagent 1 for 5 seconds, followed by eosin and methylene blue (all Thermo
Scientific) for 5 seconds and then washed in distilled water. Slides were
imaged by using an Olympus BH-2 microscope.Quantification of DEP congestion
Giemsa-stained airwaymacrophageswere scored according to how heavily
congestedwith DEPs theywere. The high contrast betweenDEP- andGiemsa-stained alveolar macrophages allowed simple visual discrimination of DEPs
and cellular contents. Cells were scored as characterized by low congestion
(<30% cytoplasmic coverage), medium congestion (30% to 60% cytoplasmic
coverage), or high congestion (>60% cytoplasmic coverage). The
scoring system was applied to 25 macrophages per mouse over several
slides. The data displayed show the mean percentage of macrophages with no
visible DEP congestion and low, medium, and high DEP congestion for 3 to 5
mice.Cell culture
J774.2 murine macrophages were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 5% FBS as previously described.47 Cell
lines were confirmed to be Mycoplasma negative before use.J774.2 OPKAs
Opsonophagocytic killing assays (OPKAs) were performed with J774.2
cells as described previously,47 with the following modifications: cells were
incubated with 20 mg of DEPs per well (40 mL of 0.5 mg/mL DEP solution)
for 2 hours before addition of opsonized pneumococci. DEP solution was son-
icated before use in the OPKAs.Human sputum macrophage phagocytic killing
assays
Participantswere given inhaled salbutamol (albuterol) via amultidose inhaler
and large volume spacer (Volumatic, Allen and Hanbury, Uxbridge, UK).
Induced sputum cells were then obtained after inhalation of nebulized 4.5%
hypertonic saline via aMultisonic Profinebulizer (Schill, Laichingen, Germany)
for a maximum of 20 minutes, as described by Kulkarni et al.48 Whole induced
sputum samples were diluted 1:1with PBS, vortexed, and centrifuged for 10mi-
nutes at 3000 rpm. The supernatant was discarded, and mucolysis carried out
with the addition of 0.1% dithiothreitol (Sigma-Aldrich, Gillingham, UK) for
10minutes, shaking at room temperature. Samples were filtered and centrifuged
for 10 minutes at 10,000 rpm. The cell pellet was subsequently resuspended in 1
mL of PBS (2% FCS) and enriched for airway macrophages by incubation with
60 mL of monocyte enrichment cocktail (RosetteSep, Stem Cell Technologies,
Cambridge, UK) and 40mL of erythrocytes. The airwaymacrophages were iso-
lated by Ficoll separation and suspended into chamberwell slides overnight. The
airway macrophages were subsequently exposed to PBS or DEPs (10 mg/mL)
for 2.5 hours before washing and addition of S pneumoniae D39 (OD 0.5) for
2 hours. The chambers were removed and slides washed before staining (Hema-
colour, Merck Millipore, UK). The cells were imaged under light microscopy
(20 macrophages per condition for each volunteer) and analyzed for mean bac-
terial load per macrophage (Image J software).Bone marrow derived macrophages assays
Murine bone marrow–derived macrophages (BMDMs) were isolated from
female C57BL/6 mice and cultured as described previously.49 On day 6, cells
were plated at 0.8 3 106 per well for use in assays. On day 7, the cells were
treated with medium or DEPs (4, 20, or 100 mg). After 24 hours, the cells
were washed with PBS to remove the DEPs and the medium was replaced.
On day 13, the cells were stimulated with D39 (8 3 106 per well). After 24
hours, supernatants were collected for cytokine quantification. The cells
were lysed and total protein was measured by using a Pierce bicinchoninic
acid protein assay kit (Thermo Scientific) according to the manufacturer’s in-
structions. TNF-a and IL-6 production were measured by ELISA (Biolegend)
and normalized to total protein content.
In vitro growth of pneumococci
For the in vitro growth experiments, pneumococci were grown in M9 min-
imal medium supplemented with 0.1% or 1% DEPs. Viable counts were per-
formed over time (2 to 7 hours) and were compared to the viable counts for
pneumococci grown in medium without supplement.
FIG 1. DEP exposure increases susceptibility to invasive pneumococcal disease. A, Experimental outline.
Female CD1micewere exposed daily to either PBS or DEPs via the intranasal route. After the third exposure,
mice were infected with 105 CFU of S pneumoniae to induce stable nasopharyngeal carriage and daily
particulate exposure (or PBS control) was continued for the duration of the experiment. B, Lungs of PBS-
exposed (top) and DEP-exposed (bottom) mice at day 7 postinfection. Lung (C), blood (D), and nasopharyn-
geal (E) CFU counts at 1, 4, 7, and 10 days postinfection are shown. Black circles indicate mice subjected to
pneumococcal infection only (P), gray squares indicate pneumococcus-infectedmice subjected to daily DEP
exposure (P1DEPs). Error bars indicate the SEM; ****P < .0001; **P < .01; *P < .05; n5 7 to 21 per group, per
time point.
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Green fluorescent protein (GFP)-tagged D39 (D39-GFP) was incubated
with DEPs for 20 minutes on an over-end rotator. Following centrifugation at
4003 g for 5minutes, unbound pneumococci were removed (supernatant) and
the pellet (containing DEPs and bound pneumococci) was washed twice with
PBS. The DEP pellet was resuspended in PBS, and FITC fluorescence was
measured by using flow cytometry. Adherence was defined as a shift in
forward scatter (FSC)-high GFP events.Scanning electron microscopy
Samples were prepared for scanning electron microscopy as follows. The
bacteria were incubated with DEPs for 15 minutes before washing in PBS (as
described earlier) and fixation in 4% (wt/vol) paraformaldehyde and 2.5% (wt/
vol) glutaraldehyde in 0.1Mphosphate buffer (pH 7.4). After another wash step,
the bacteria and DEPs were pipetted onto poly-L-lysine–coated glass coverslips
before stainingwith reduced osmium (2%osmium tetroxide in distilledwater1
1.5% potassium ferrocyanide in 0.1M PB) followed by 2% (wt/vol) aqueous
uranyl acetate. Dehydration was performed in graded ethanol followed by hex-
amethyldisilazane. To prevent precipitation artifacts the samples were washed
copiously with double-distilled water between each staining step.
Coverslips were attached to scanning electron microscopy stubs and then
sputter-coated with 10 nm of AuPd (QuorumTechnologies Q150T. Lewes,
UK). Secondary electron scanning electron microscopy imaging was per-
formed in a Quanta 250 FEG (FEI, Hillsboro, Ore) at low vacuum (0.53 Torr)
with an acceleration voltage of 5 kV.Statistical analysis
All statistical analysis was carried out using GraphPad Prism 7 software
(GraphPad Inc, La Jolla, Calif). The Mann-Whitney U test and ANOVAwithKruskall-Wallis posttest were performed when comparing 2 and 3 experi-
mental groups, respectively. Error bars represent the SEM.RESULTS
Inhaled DEP exposure promotes IPD
In our experiments, CD1 mice were exposed to 80 mg of DEPs
in 40 mL of PBS once daily for 3 days before they were infected
with S pneumoniae (serotype 2, strain D39) and then continuing
daily for the duration of the experiment (Fig 1, A). Mice were in-
fected with 105 CFU of D39 in 10 mL of PBS to induce asymp-
tomatic nasopharyngeal carriage without dissemination to the
lower respiratory tract.50,51 Deposition of particulates in the lungs
of DEP-exposed mice was clearly visible throughout infection
(Fig 1, B). DEP-exposed mice had significantly higher bacterial
loads in the lung at day 4 postinfection (P5 .0001), and this trend
was continued at day 7 (P5 .0001) and day 10 postinfection (P5
.05, Fig 1, C). Lung bacterial loads between 103 and 107 CFU
were reported in 90% of DEP-exposed mice (20 of 22) at day 4
postinfection and 90% of mice (10 of 11) at day 7 postinfection.
The mean values for these time points were 4.6 3 104 and
2.7 3 104 CFU, respectively. In contrast, only 10% to 20% of
sham-treated mice had pneumococci in their lungs at these time
points. By day 10 postinfection, only 55% of DEP-exposed
mice (5 of 9) had pneumococci in their lungs and the mean bac-
terial load was 2.2 3 103 CFU, suggesting that DEP-exposed
mice retain the capacity to clear infection from their lungs over
time. In addition, DEP-exposed mice developed bacteremia by
FIG 2. DEP exposure drives early inflammation in the lungs that is exacerbated in the context of infection.
A-F, TNF-a, IFN-g, keratinocyte chemoattractant/human growth-regulated oncogene (KC/GRO), macro-
phage inflammatory protein 2 (MIP-2), IL-1b, and IL-6 levels in lung homogenate were measured for mice
subjected to pneumococcal infection only (P, black circles), pneumococcus-infected mice subjected to daily
DEP exposure (P1DEPs, gray squares), andmice subjected to daily DEP exposure in the absence of infection
(DEPs, white triangles). G, Representative images of lungs from sham-exposed (left) and DEP-exposed
(right) mice at day 7 postinfection following hematoxylin and eosin staining.H-J, The number of neutrophils
(CD451Gr11), macrophages (CD451F4/801CD11b1), and regulatory T cells (Tregs) (CD451CD41Foxp31) in
lung cell suspension was measured by flow cytometry for mice subjected to pneumococcal infection
only (P, black circles), pneumococcus-infected mice subjected to daily DEP exposure (P1DEPs, gray
squares) and mice subjected to daily DEP exposure in the absence of infection (DEPs, white triangles).
The gating strategy is shown in Fig E2. Error bars indicate the SEM; ****P < .0001; ***P < .001; **P < .01;
* P < .05. Scale bars represent 200 microns, n 5 7 to 10 per group, per time point.
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FIG 3. DEP-congested alveolar macrophages have reduced phagocytic ability. A, Alveolar macrophages
isolated by BAL from PBS- (top) and DEP- (middle) exposed mice 7 days postinfection. Alveolar macro-
phages isolated from DEP-exposed mice 14 days after the last DEP exposure (bottom), suggesting that
clearance of DEPs frommacrophages is a slow process. B, Scoring guide for alveolar macrophages accord-
ing to how congested with DEPs they are. No uptake of DEPs, low (<20% of cell cytoplasm is congested with
DEPs), medium (20% to 50% congestion), and high (>50% congestion) uptake were scored as shown. C, Pro-
portion of alveolar macrophages graded as characterized by low, medium, or high congestion at day 7 post-
infection following daily DEP exposure. D, Proportion of alveolar macrophages graded as characterized by
low, medium, or high congestion 14 days after the last DEP exposure. E, Pneumococcal opsonophagocytic
ability of mouse J774.2 macrophages treated with either PBS (control) or DEPs. F, Uptake of DEPs (bottom)
versus control (PBS-treated) airway macrophages isolated from sputum of human volunteers. G, Phagocy-
tosis of pneumococci by human airway macrophages pretreated with either PBS (control) or DEPs. Error
bars indicate the SEM; ***P < .001; **P < .01; *P < .05. For each experimental condition, n 5 3 to 5.
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Despite the association between DEP exposure and high lung
and/or blood bacterial loads, there was no significant difference
in nasopharyngeal bacterial load compared with that in PBS-
treated mice (Fig 1, E), nor was there a difference in survival
time (P 5 .467, see Fig E1 in this article’s Online Repository at
www.jacionline.org).DEP exposure is associated with lung inflammation
DEPs were inflammatory in the absence of pneumococcal
infection, leading to significantly increased levels of TNF-a, IFN-
g, keratinocyte chemoattractant/human growth-regulated onco-
gene (KC/GRO), macrophage inflammatory protein 2, and IL-1b
compared with the levels in pneumococcus-infected control mice
at day 1 postinfection (Fig 2, A-E). By day 4 and 7 postinfection,
FIG 4. DEP exposure increases proinflammatory cytokine secretion by BMDMs. Murine BMDMs were
treated with 4, 20, or 100 mg of DEPs. After 24 hours of exposure, the cells were washed to remove DEPs
from the culture. The BMDMs were stimulated with D39 on day 6 following DEP exposure. IL-6 and TNF-a
production was measured by ELISA. A, Uptake of DEPs (4, 20, or 100 mg) by murine BMDMs following 24-
hour treatment. B-C, TNF-a and IL-6 in culture supernatant 24 hours after pneumococcal stimulation
(normalized against total protein production). Results represent 4 independent experiments. Bars indicate
mean cytokine production; error bars represent the SEM; ***P < .001; n 5 4 per condition).
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higher levels of these proinflammatory cytokines than the unin-
fected mice exposed only to DEP, and both groups had higher
levels of these cytokines compared to the sham-treated
pneumococcus-infected controls (Fig 2 A-F). These data suggest
that DEP exposure further exacerbates proinflammatory cytokine
production during active lung infection. IL-10, IL-12p70, and
IL-17Awere also included in the Meso Scale Discovery cytokine
array; however, low levels of IL-10 and IL-12 were measured at
all time points, with higher titers of IL-17A measured at day 7
only (data not shown). The proinflammatory nature of DEP
exposure alone is also apparent from lung histology, with marked
influx of leukocytes surrounding DEPs deposited within the lung
tissue (Fig 2,G). As expected, themajority of DEP depositionwas
in close proximity to the respiratory airways. DEP exposure was
accompanied by neutrophil infiltration into the lungs at day 1 and
day 7 postinfection (Fig 2,H). There was no significant difference
in the number of macrophages at any time point (Fig 2, I);
however, therewas an increase in the number of regulatory T cells
in the lungs of DEP-exposed mice compared with the number in
the lungs of the sham-treated mice at day 1 and 4 postinfection
(Fig 2, J), presumably to counteract the proinflammatory
response (see Fig E2 in this article’s Online Repository at
www.jacionline.org for gating strategy).52 These proinflamma-
tory responses in the lung are likely to cause significant tissue
damage, permitting the bacterium to translocate into the blood
stream.46,52,53Alveolar macrophages become congested with
DEPs, which reduces their phagocytic function and
leads to increased production of proinflammatory
cytokines
Despite a robust inflammatory response and increased
numbers of lung neutrophils (Fig 2), the host is unable to clear
S pneumoniae from the lungs following DEP exposure.
Macrophages and neutrophils are essential for clearance of
pathogens and debris in the lungs,54,55 and reduction of alveolar
macrophage phagocytic function is known to permit uncontrolled
replication of the pneumococcus in the lungs.56,57 We
hypothesized that the pulmonary phagocytes become congested
with particulate following DEP exposure, which could reduce
their phagocytic ability and thus impair bacterial clearance. To
test this, airway macrophages and neutrophils were isolated by
BAL from mice exposed to DEPs for 7 days (Fig 3, A). More
than half of the alveolar macrophages (53%) were congested
with DEPs; a small proportion of macrophages (13%) were
heavily congested with DEPs (as defined in Fig 3, B), whereas a
further 23% and 17% had medium and low DEP congestion,
respectively (Fig 3, C). Interestingly, this observation appeared
to be unique to airway macrophages, as neutrophils were not
congested with DEPs (see Fig E3 in this article’s Online
Repository at www.jacionline.org). This may suggest that
macrophages are the most important phagocytic cell for DEP
clearance, that neutrophils are capable of rapidly clearing
FIG 5. Pneumococci adhere to DEPs in vitro. A-C, Following coincubation of D39 with DEPs, pneumococci
(highlighted in purple) can be seen in close proximity to the particulate by scanning electron microscopy.
Original images are shown in Fig E6. D-G, Flow cytometry plots for D39-GFP without slow-speed
centrifugation step (D), coincubated DEPs and D39-GFP after slow-speed centrifugation (E), D39-GFP only
after slow-speed centrifugation (F), and DEPs alone (G) are shown. The percentages of unbound and
FSC-high GFP events in (D) and (E) are displayed in (H) and (I), respectively.
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and rapid turnover of neutrophils.58 To determine how quickly
DEPs are cleared from airway macrophages, mice were exposed
to DEPs for a total of 3 consecutive days and BAL fluid was
obtained 1, 3, 7, or 14 days after the last DEP exposure. Even after
14 days, the majority of airway macrophages (67%) were still
congested with DEPs (Fig 3, D), suggesting that DEP exposure
may affect macrophage function for prolonged periods,
potentially leaving the host susceptible to a variety of respiratory
infections.
To determine whether particulate congestion could impair
bacterial phagocytosis by airway macrophages, we performed
OPKAs using mouse J774.2 macrophage cells. Cells were
pre-exposed to DEPs for 2 hours before addition of opsonized
D39. Viable counts were determined following overnight growth
on blood agar base plates. Under these conditions, sham exposureresulted in 17% pneumococcal phagocytosis; however,
pneumococcal clearance was completely ablated following DEP
exposure (Fig 3, E). There was no difference in viability of DEP-
and sham-exposed cells (see Fig E4 in this article’s Online
Repository at www.jacionline.org), suggesting that the altered
phagocytic ability was not due to a reduction in cell viability
following DEP exposure. We also performed a similar phagocytic
killing assay with induced sputum macrophages isolated from
healthy human volunteers. Uptake of DEPs by these macrophages
was observed (Fig 3, F), and pneumococcal phagocytosis was
significantly impaired compared with that by PBS-exposed
macrophages (Fig 3, G). These data suggest that the impaired
innate immune mechanisms observed in our mouse model are
also at play in humans.
We also sought to determine the effect of DEP exposure on
proinflammatory cytokine production by macrophages. Murine
FIG 6. DEPs sustain survival of pneumococci in vitro. Viable count for pneu-
mococci in M9 minimal medium supplemented with 1% DEPs (M9 1 1%
DEPs, solid black line) and 0.1% DEPs (M9 1 0.1% DEPs, broken black
line) as compared with M9medium without supplement (M9, broken green
line) over 7 hours. Graph represents 4 independent experiments.
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after which uptake of DEPs was visible (Fig 4, A). Six days later,
the BMDMs were stimulated with S pneumoniae or medium
alone and TNF-a and IL-6 production in culture supernatants
was measured by ELISA. Production of TNF-a and IL-6
following stimulation with pneumococci was increased with
exposure to higher concentrations of DEPs (Fig 4,B-C). However,
no TNF-a or IL-6 was measured in the culture supernatants of
DEP-exposed BMDMs stimulated with medium alone (data not
shown). These data suggest that DEP-congested macrophages
produce higher levels of inflammatory cytokines following
microbial challenge than do unexposed macrophages, which is
likely to contribute to the proinflammatory environment of the
lung observed in DEP-exposed, pneumococcus-infected mice.Pneumococci adhere to DEPs in vitro
The increased lung and blood bacterial loads of DEP-exposed
mice described in Fig 1were apparent whenmicewere exposed to
DEPs on a daily basis both before and after induction of
pneumococcal carriage. The same effects were not observed,
however, when mice were exposed to DEPs for 6 consecutive
days before infection (with no postinfection DEP exposure)
(see Fig E5 in this article’s Online Repository at
www.jacionline.org), despite being subjected to the same number
of DEP exposures (6 in total). We therefore hypothesized that
DEPs could be binding to pneumococci as they pass through
the nasopharynx, thus dragging bacteria down into the lungs. To
determine whether pneumococci could bind DEPs, we incubated
D39 or D39-GFP with DEPs on an over-end rotator for
20 minutes. Samples were centrifuged at 400 g for 5 minutes to
pellet DEPs, and unbound pneumococci were removed with the
supernatant. The pellet was washed with PBS and samples were
prepared for scanning electron microscopy or flow cytometry
analysis. We observed adherence of pneumococci to DEPs by
scanning electron microscopy (Fig 5, A-C, see Fig E6 in this
article’s Online Repository at www.jacionline.org for original
image) and these observations were confirmed by using flow
cytometry (Fig 5, D-I). Coincubation of D39-GFP with DEPs
led to an increase in the size (FSC) of a proportion of recorded
GFP-positive events, suggesting binding of bacteria to the larger
DEPs (Fig 5,D-E). We also confirmed that centrifugation at 400 g
does not pellet pneumococci in the absence of DEP adherence
(Fig 5, F), and we showed that DEPs alone do not fluoresce at
this wavelength (Fig 5, G). These data suggest that theincrease in high-FSC GFP-positive events in the slow-speed
centrifugation pellet of coincubated DEPs and D39-GFP (Fig 5,
H-I) was the result of pneumococci adhering to the particulate.
Together, these data suggest that inhaled DEPs can drag
pneumococci from the nasopharynx downward into the lower
respiratory tract, leading to increased susceptibility to pneumonia
and bloodstream infection.DEPs sustain survival of pneumococci
We also investigated the effect of DEP exposure on
pneumococcal survival. Bacteria were incubated in M9 minimal
medium supplemented with either 1% or 0.1% DEPs. Viable
counts were calculated at 0, 2, 4, 6, and 7 hours after inoculation
and compared with the counts with minimal medium without
supplement (M9). For the M9 group, the CFU count fell rapidly
over time, and by 6 hours no bacteria were detected. In contrast,
the CFU count decreased at a substantially slower rate when
pneumococci were maintained in minimal medium supplemented
with 0.1%or 1%DEPs (M91 0.1%or 1%DEPs). The CFU count
for the M9 plus 1% DEP group was significantly higher than that
of the M9 group at 4, 6, and 7 hours after inoculation (P5 .0066,
.0005, and .0009 respectively, Fig 6). These data suggest that
DEPs may provide metabolites for pneumococci, promoting
survival within the lung. DEPs contain a mixture of polycyclic
aromatic hydrocarbons and nitro-substituted polycyclic aromatic
hydrocarbons, among other chemical compounds,59 although
further analysis is required to identify which components promote
survival of the pnemococcus. This is the first report, to our
knowledge, demonstrating that pneumococci are able to use
environmental pollutants for metabolism.Inhaled DEP exposure increases susceptibility to
invasive pneumococcal pneumonia in resistant
hosts
To expand on our previous findings showing that exposure to
DEPs increases susceptibility to IPD, we repeated our in vivo
experiments using a mouse strain normally resistant to
pneumococcal pneumonia.52,53 In this model, resistant BALB/c
mice were exposed daily to DEPs and lung infection was induced
by intranasal infection with 1 3 106 CFU in 50 mL of PBS,
meaning that both the DEPs and pneumococci were deposited
directly into the lungs. There was no significant difference in lung
or blood bacterial loads of DEP-exposed mice compared with those
of the sham (PBS)-treated mice at 24 hours postinfection; however,
by 72 hours postinfection, the majority of sham-treated mice had
cleared the infection, whereas 80% of the DEP-exposed mice
(12 of 15) still harbored pneumococci in their lungs (Fig 7, A). In
addition, 60% of the DEP-exposed mice (9 of 15) had bacteremia
at 72 hours postinfection, whereas none of the sham-treated mice
had bacteremia at this time point (Fig 7, B). This recapitulates our
earlier findings, showing that when DEPs and pneumococci are
both present in the lungs, bacterial clearance is impaired, even in
pneumonia-resistant mouse strains, which normally have robust
bacterial clearance mechanisms in place.DISCUSSION
The results described here show that inhaled exposure to DEPs
alters pneumococcal interactions with its host, promoting
transition from asymptomatic nasopharyngeal commensal to
FIG 7. Daily inhalation of DEPs increases lung and blood bacterial loads during pneumococcal pneumonia
in resistant mice. BALB/c mice were exposed daily to PBS or DEPs before (and following) infection
with pneumococci. Mice were culled at 24 or 72 hours postinfection to assess lung (A) and blood (B)
CFUs.**P < .01; NS 5 nonsignificant; n 5 12 to 15 per group, per time point.
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carriage, the pneumococcus is ordinarily restricted to the
nasopharynx and progression to the lungs is rare.49 However,
DEP exposure significantly increases the bacterial load in the
lung, with 90% of DEP-exposed mice displaying high bacterial
loads at day 4 and 7 postinfection. This increase in lung CFU
burden leads to bacteremia in approximately a third of mice by
day 4 and half by day 7 postinfection. Surprisingly, despite
bacteremia, there was no significant difference in the survival of
DEP-exposed mice compared with that of the control mice. There
was also no significant difference in bacterial load within the
nasopharynx at any time point, suggesting that the major effect
of DEP inhalation is due to events within the lower airways (ie,
the creation of a proinflammatory environment within the lungs,
combined with the congestion of airway macrophages). In our
in vivo experiments, we mimicked ambient air levels of fine PM
recorded in cities across Western Europe (;20 mg/m3 per
day).60 The theoretical exposure for people living in these areas
is 200 mg per day, assuming a daily intake of 10,000 m3 of air
for an average adult, which is an approximately equivalent
weight/volume ratio for a 30-gmouse compared to a 75-kg human
(2.67 mg DEPs per gram body mass). Although only a proportion
of PM may reach the lungs because of various clearance
mechanisms (eg, mucus and cilia), meaning that the experimental
exposure presented in this article may be closer to much higher
levels of PM, these findings suggest that under the right
circumstances (dependent on age, genetics, and coinfection
status), exposure to environmental particulates such as DEPs
could significantly alter the outcome of pneumococcal carriage,
increasing susceptibility to invasive disease in humans.
Our data suggest that DEP exposure causes an early increase
(day 1 postinfection) in lung proinflammatory cytokine
production relative to that in PBS-treated mice. The inflammatory
environment is exacerbated by active lung infection (of the
DEP-exposed, pneumococcus-infected mice) at day 4 and 7
postinfection. This proinflammatory response is likely to cause
substantial tissue damage, permitting the bacterium to access the
blood stream.46,52,53 This is corroborated by the lung histology
images, which show a substantial influx of leukocytes to areas
with high DEP deposition, and by our flow cytometry data, which
also show increased neutrophil influx compared with that in
sham-treated mice at multiple time points. These observations
are supportedbyprevious reports,which found thatDEP inhalation
causes influx of both neutrophils and macrophages to the lung andincreased expression of IL-4, IL-6, IL-13, TNF-a, and NF-kB by
lung cells, as well as an upregulation of mucus production and
deposition of collagen and elastic fibers in the alveolar septum.37,61
These data suggest that tissue remodeling occurs following
DEP-driven inflammation. There is also a strong body of
evidence to suggest that DEP inhalation can increase lung
inflammation and bronchial hyperresponsiveness caused by house
dustmite and soybean allergen.39,41,42 These data suggest thatDEP
exposuremay exacerbate allergic airway inflammation, generating
a mixed TH2/TH17 response.
39,41,42 Exposure to DEPs also
resulted in increased levels of markers for both allergic
(eosinophilia and IL-5 production) and nonallergic (macrophage
chemoattractant protein-1, IL-8, and neutrophilia) inflammation
in atopic human volunteers.40 Alarmingly, DEP exposure has
also been shown to alter the gene expression profile of human
bronchial epithelial cells in vitro, with alterations in genes
associated with metabolism of lipids and xenobiotics, as well as
changes in inflammatory cytokines such as IL-1b,62 suggesting
that exposure to pollutants could have far-reaching and
long-lasting consequences.
We observed that DEPs are adhesive by nature, and we showed
that pneumococci bind to DEPs following in vitro incubation. It is
possible that DEPs adhere to pneumococci as they pass through
the nasopharynx, thereby pulling bacteria down into the lung.
In support of this, we did not observe pneumococci in the lungs
of mice that were exposed to DEPs only before infection. These
mice were subjected to the same number of DEP exposures as
those in Fig 1 (6 in total); however, exposure was restricted to
preinfection. It is reasonable to assume therefore that this
phenomenon of bacterial transfer to the lower respiratory tract
following adherence to PM may also occur in human carriage,
as airborne DEPs mix with moisture in the nasal cavity as we
breathe in. This effect does not appear to alter the bacterial load
within the nasopharynx, presumably because only small numbers
of planktonic pneumococci (thosewhich are not strongly attached
to host cells within the nasopharynx) are transferred to the lungs.
Upon reaching the lungs, the pneumococci are able to replicate,
reaching the higher CFU levels reported here. We also
demonstrate that pneumococci can utilize DEPs as a source of
metabolites in the absence of other energy sources, so it is
possible that the daily administration of DEPs in our in vivomodel
is aiding bacterial survival within the lungs. This is the first report,
to our knowledge, demonstrating that pneumococci are able to use
environmental pollutants as a source of metabolites.
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utilize DEPs as a source of metabolites is unlikely to be the sole
reason for progression toward IPD. We show that airway
macrophages become congested with DEPs following intranasal
exposure, and that this reduces their phagocytic function, which
would permit increased replication of the bacterium in the lungs
given the key role of alveolar macrophages in host anti-
pneumococcal defense.56,57 We also found that DEP exposure
reduces the phagocytic ability of human airway macrophages,
suggesting that impaired bacterial clearance by airway
macrophages following inhaled particulate exposure may also
potentially affect pneumococcal infection outcome in humans.
Of course, there are differences in phenotype between induced
sputum macrophages and alveolar macrophages from the more
distal airways63; however, both macrophage populations exhibited
significant impairment in phagocytosis following exposure to
inhaled DEPs which would clearly contribute to susceptibility to
pneumococcal disease. Congestion of airway macrophages and
reduced phagocytosis following exposure to DEPs has been
reported in other infection models, such as P aeruginosa and
L monocytogenes.43,44 Our data build on these observations,
showing that exposure to DEPs at levels equivalent to the levels
of fine PM measured in cities across Western Europe, can alter
pneumococcal infection outcome, promoting a switch from
asymptomatic nasopharyngeal carriage to dissemination to
the lungs and blood, thus tipping the balance toward invasive
disease. Together, these studies suggest that exposure to DEPs
can alter host-pathogen responses for a range of respiratory
bacteria.
In addition to phagocytosis of bacteria, airway macrophages
play a critical role in removing apoptotic and necrotic cells while
also controlling neutrophil infiltration and cytokine production in
the lungs during pneumococcal pneumonia.64 This might explain
the increase in proinflammatory cytokines in DEP-exposed,
infected mice relative to the level in sham-treated mice, as
congested alveolar macrophages are unable to control neutrophil
influx and proinflammatory cytokine production. Indeed, our flow
cytometry data show that there is an increase in neutrophils both
early on (day 1) and later (day 7) during infection in the
DEP-exposed mice.
We found that even 2weeks after the last DEP exposure, airway
macrophages remain congested with DEPs, suggesting that DEP
clearance by macrophages themselves and/or clearance of
congested macrophages by other cells is a slow process. These
data suggest that DEP exposure may have a long-term effect on
the phagocytic function of airway macrophages, potentially
leaving the host susceptible to a variety of respiratory infections.
In addition, we show that DEP congestion leads to increased
TNF-a and IL-6 secretion by BMDMs in response to
pneumococcal challenge. Taken together with the clearance
data, this suggests that long-term congestion of airway
macrophages could lead to prolonged lung inflammation and
elevated risk of pneumococcal disease even weeks or months
following DEP exposure. In the context of pneumococcal
pneumonia, uncontrolled lung inflammation can grant the
pneumococcus access to the blood stream, which can lead to
bacteremia and sepsis.52 It is likely that the combination of
reduced airway macrophage phagocytic function and increased
inflammation observed in our model allows the bacterium to
replicate to high numbers in the lung and permits the
pneumococcus to access the blood stream. Our experiments usinga pneumococcal pneumonia model in resistant (BALB/c) hosts
recapitulate these findings, showing that when DEPs and
pneumococci are both present in the lungs, bacterial clearance
is impaired, probably mainly due to reduced function of alveolar
macrophages, which are key in controlling pneumococcal
infection,57,64,65 and that DEPs are able to sustain bacterial
survival and proliferation.
In summary, we show that daily inhaled exposure to DEPs
disrupts asymptomatic nasopharyngeal carriage in mice and
promotes pneumococcal dissemination to the lungs and blood.
Our results show that pneumococci are transported from the
nasopharynx to the lungs following adherence toDEPs and are able
to utilize DEPs as a source of metabolites, promoting survival
within the lungs. We demonstrate that inhaled DEPs lead to influx
of neutrophils in the lungs, even in the absence of infection.
However, airway macrophages (isolated from both mouse and
human), which are key for control of pneumococcal infection,
become congested with DEPs, which significantly reduces their
phagocytic function while promoting a proinflammatory
environment within the lungs. This results in increased
pneumococcal loads in the lungs and associated lung tissue
inflammation leading to bacterial entry into the bloodstream.
These data provide compelling evidence that exposure to
particulate pollutants such as DEPs can alter the relationship
between the host and pneumococcus, tipping the balance toward
invasive pathogenicity. Given that 91% of the world’s population
inhabit areas where the air pollution exceeds World Health
Organization guideline limits,19 reducing the amount of airborne
pollution has the potential to reduce the global burden of
pneumococcal disease significantly. A recent global assessment
of the effect of environmental pollution on health commissioned
by the World Health Organization found that 35% of lower
respiratory tract infections are due to modifiable environmental
factors.66 Such modifications would include reducing airborne
pollution.66 Therefore, our data add impetus to coordinate global
efforts to reduce airborne pollution and transition toward more
sustainable energy sources that produce cleaner air.
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Key messages
d Daily inhaled exposure to DEPs increases susceptibility to
pneumococcal disease by disrupting the delicate balance
that exists in the nasopharynx during asymptomatic
carriage.
d DEPs cause lung inflammation and is readily ingested by
airway macrophages, which significantly reduces their
phagocytic function, leading to increased pneumococcal
loads within the lungs and translocation into blood.REFERENCES
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FIG E1. Survival of PBS-exposed (P) and DEP-exposed (P1DEP) mice
following pneumococcal carriage infection (n 5 24).
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FIG E2. Gating strategy for neutrophils (CD451Gr11), macrophages (CD451F4/801CD11b1) (A) and Tregs
(CD451 CD41 Foxp31) (B) in lung cell suspensions.
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FIG E3. Characterization of neutrophils in BAL fluid of DEP-exposed mice. Cells isolated in BAL fluid were
Giemsa-stained, and neutrophils were identified by their lobed nucleus. Scale bars represent 10 microns.
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FIG E4. Viability of J774.2 cells is not affected by DEP exposure. J774.2 macrophages were treated for 2
hours with either DEPs (left, middle) or sham-treated (right) and stained with Trypan blue to confirm that
DEP exposure does not affect viability of cells. Dye is taken up by a minority of cells (closed arrows), which
indicates cell death. DEP uptake by J774.2 macrophages is also visible (open arrows). Scale bars represent
10 microns.
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FIG E5. Exposure of mice to DEPs before infection only does not result in bacterial dissemination into the
lungs or blood. Mice were exposed to DEPs for 6 days before induction of pneumococcal carriage (no DEP
exposure after infection) and culled at day 4 after infection to assess nasopharyngeal (A), lung (B), and blood
(C) CFUs.
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FIG E6. Scanning electron microscopy images showing adherence of pneumococci to DEPs.
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